Chemomab Therapeutics (CMMB) to Release Earnings on Thursday

Chemomab Therapeutics (NASDAQ:CMMB) is scheduled to be releasing its earnings data before the market opens on Thursday, May 9th. Analysts expect Chemomab Therapeutics to post earnings of ($0.20) per share for the quarter.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14. During the same period in the prior year, the firm earned ($0.72) earnings per share. On average, analysts expect Chemomab Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Chemomab Therapeutics Trading Up 4.2 %

Shares of Chemomab Therapeutics stock opened at $0.89 on Wednesday. Chemomab Therapeutics has a 1-year low of $0.42 and a 1-year high of $1.89. The firm’s 50-day moving average price is $0.74 and its two-hundred day moving average price is $0.64. The stock has a market capitalization of $9.82 million, a price-to-earnings ratio of -0.42 and a beta of 0.39.

Analyst Ratings Changes

Separately, Oppenheimer raised Chemomab Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Monday.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).